Lymphoma
Conditions
Keywords
childhood nodular lymphocyte predominant Hodgkin lymphoma, stage I childhood Hodgkin lymphoma, stage II childhood Hodgkin lymphoma
Brief summary
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, vinblastine, and prednisolone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Surgery to remove involved lymph nodes may be an effective treatment for young patients with nodular lymphocyte-predominant Hodgkin lymphoma. PURPOSE: This phase IV trial is continuing to study the side effects of giving surgery alone or giving surgery with cyclophosphamide, vinblastine, and prednisolone compared with giving cyclophosphamide, vinblastine, and prednisolone alone in treating young patients with stage IA or stage IIA nodular lymphocyte-predominant Hodgkin lymphoma.
Detailed description
OBJECTIVES: Primary * Determine the 5-year event-free survival of children or adolescents with stage IA or IIA nodular lymphocyte-predominant Hodgkin lymphoma treated with surgery alone or with cyclophosphamide, vinblastine, and prednisolone. Secondary * Determine if this regimen results in a decrease in overall survival rates, in significant upstaging at relapse, or increased rates of histological transformation in these patients. OUTLINE: * Group 1 (patients with stage IA disease only): Patients undergo surgical resection of the involved lymph nodes. Patients who achieve complete resection then enter follow-up (watch and wait); patients who do not achieve complete resection enters group 2 treatment. * Group 2 (patients with stage IIA disease or incompletely resected stage IA disease): Patients receive cyclophosphamide, vinblastine, and prednisolone for 3 courses. Patients with good response enter follow-up (watch and wait). Patients without a good response are taken off protocol. After completion of study treatment, patients are followed-up periodically.
Interventions
DRUGcyclophosphamide
DRUGprednisolone
DRUGvinblastine sulfate
OTHERwatchful waiting
PROCEDUREtherapeutic conventional surgery
Sponsors
Deutsche Krebshilfe e.V., Bonn (Germany)
Euronet Worldwide
Christine Mauz-Körholz
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No
Inclusion criteria
* nodular lymphocyte-predominant Hodgkin's lymphoma confirmed by reference pathology. * initial stage IA/IIA (according to local staging) or relapse stage IA or IIA and residual tumour after relapse biopsy and no additional surgery planned in nLP patients relapsing after surgery alone * patient aged under 18 years at time of diagnosis * written informed consent of the patient and/or the patient's parents or guardian according to national laws
Exclusion criteria
* pre-treatment of Hodgkin's lymphoma differing from study protocol * Any extra-nodal involvement * Inability to fulfil protocol requirements for imaging (CT, MRI, FDG-PET) at staging and response assessment * known hypersensitivity or contraindication to study drugs * prior chemotherapy or radiotherapy * Current or recent therapy (within 30 days prior to the start of trial treatment) with steroids * Current or recent (within 30 days prior to the start of trial treatment) treatment with another investigational drug or participation in another investigational trial * other (simultaneous) malignancies * severe concomitant diseases (e.g. immune deficiency syndrome) * known HIV positivity * pregnancy and / or lactation * females who are sexually active refusing to use effective contraception (oral contraception, intrauterine devices, barrier method of contraception in conjunction with spermicidal jelly or surgical sterile) (except for surgery only)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival | 5 years | Time from treatment start until relapse/progression, secondary malignancy or death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Significant upstaging at relapse defined as development of B-symptoms, extranodal disease, or relapse higher than stage II | 5 years | Stage greater than IIA at relapse diagnosis |
| Overall survival | 5 years | Time from treatment start until death |
| Common Toxicity criteria toxicity Levels of therapy elements | 5 years | Evaluation of AEs, SAEs atc. according to CTC |
| Complications of surgery | 5 years | Listing of surgical complications |
Countries
Germany
Outcome results
None listed